An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults

Journal of Substance Abuse Treatment

Volumn 48, Issue 1, 2015, Pages 96-103

  Kollins, Scott H ^a   Schoenfelder, Erin N ^b   English, Joseph S ^a   Holdaway, Alex ^a   Van Voorhees, Elizabeth ^c   O'Brien, Benjamin R ^a   Dew, Rachel ^a   Chrisman, Allan K ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Cannabis; Delta 9 tetrahydrocannabinol (THC); Methylphenidate; Prescription stimulant

Indexed keywords

AMPHETAMINE; DRONABINOL; METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; ATTENTION; BLOOD PRESSURE; CANNABIS USE; COGNITION; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPLORATORY RESEARCH; FEMALE; HEART RATE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; VITAL SIGN; WORKING MEMORY; YOUNG ADULT; DRUG EFFECTS; DRUG INTERACTION; PILOT STUDY; PSYCHOMOTOR PERFORMANCE;

ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; PILOT PROJECTS; PSYCHOMOTOR PERFORMANCE; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 84922795242     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.07.014     Document Type: Article

References (76)

1. Abreu M.E., Griffiths R.R. Drug tasting may confound human drug discrimination studies. Psychopharmacology 1996, 125(3):255-257. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8815961).
2. Alexander D., Leung P. The Marijuana Screening Inventory (MSI-X): concurrent, convergent and discriminant validity with multiple measures. The American Journal of Drug and Alcohol Abuse 2006, 32(3):351-378. (Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16864468).
3. Barrett S.P., Darredeau C., Bordy L.E., Pihl R.O. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 2005, 50(8):457-461. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16127963).
4. Barrett S.P., Darredeau C., Pihl R.O. Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacology 2006, 21(4):255-263. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16783813).
5. Biederman J., Spencer T.J., Wilens T.E., Prince J.B., Faraone S.V. Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45(10):1147-1150. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16840880).
6. Bohn M.J., Babor T.F., Kranzler H.R. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. Journal of Studies on Alcohol 1995, 56(4):423-432. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7674678).
7. Bossong M.G., van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34(3):759-766. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18754005).
8. Chait L.D., Zacny J.P. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology 1992, 107(2-3):255-262. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1319601).
9. Charach A., Yeung E., Climans T., Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. Journal of the American Academy of Child and Adolescent Psychiatry 2011, 50(1):9-21. 10.1016/j.jaac.2010.09.019.
10. Coghill D.R., Seth S., Pedroso S., Usala T., Currie J., Gagliano A. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: Evidence from a systematic review and a meta-analysis. Biological Psychiatry 2013, 10.1016/j.biopsych.2013.10.005.
11. Conners C.K. The Conners continuous performance test 1994.
12. Cooper W.O., Habel L.A., Sox C.M., Chan K.A., Arbogast P.G., Cheetham T.C., et al. ADHD drugs and serious cardiovascular events in children and young adults. The New England Journal of Medicine 2011, 365(20):1896-1904. 10.1056/NEJMoa1110212.
13. Curran H.V., Brignell C., Fletcher S., Middleton P., Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002, 164(1):61-70. 10.1007/s00213-002-1169-0.
14. Faraone S.V., Biederman J., Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. Journal of Clinical Psychopharmacology 2002, 22(5):468-473. (Retrieved from, http://www.ncbi.nlm.nih.gov/pubmed/12352269).
15. Faraone S.V., Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child and Adolescent Psychiatry 2010, 19(4):353-364. 10.1007/s00787-009-0054-3.
16. Faraone S.V., Spencer T., Aleardi M., Pagano C., Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology 2004, 24(1):24-29. 10.1097/01.jcp.0000108984.11879.95.
17. First M.B., Gibbon M., Williams J.B.W., Spitzer R.L. SCID Screen Patient Questionnaire - Extended version 1997, Multi-Health Systems, Inc., North Tonawanda, NY.
18. Foltin R.W., Fischman M.W. The effects of combinations of intranasal cocaine, smoked marijuana, and task performance on heart rate and blood pressure. Pharmacology Biochemistry and Behavior 1990, 36(2):311-315. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2162543).
19. Habel L.A., Cooper W.O., Sox C.M., Chan K.A., Fireman B.H., Arbogast P.G., et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011, 306(24):2673-2683. 10.1001/jama.2011.1830.
20. Hammerness P., Fried R., Petty C., Meller B., Biederman J. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. Child Neuropsychology 2013, 10.1080/09297049.2013.790359.
21. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Foltin R.W. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 2005, 181(2):237-243. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15830233).
22. Hart C.L., Ward A.S., Haney M., Comer S.D., Foltin R.W., Fischman M.W. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology 2002, 164(4):407-415. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12457271).
23. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future national survey results on drug use, 1975-2005. Volume II: College students and adults ages 19-45 (NIH Publication No. 06-5884) 2006.
24. Kaufman A.S., Kaufman N.L. Kaufman Brief Intelligence Test, Second Edition (KBIT-II) 2004, AGS Publishing, Circle Pines, MN.
25. Kollins S.H., English J., Robinson R., Hallyburton M., Chrisman A.K. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology 2009, 204(1):73-83. 10.1007/s00213-008-1439-6.
26. Kollins S.H., Rush C.R. Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. Pharmacology Biochemistry and Behavior 1999, 64(2):319-326. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10515308).
27. Kollins S.H., Rush C.R. Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biological Psychiatry 2002, 51(2):143-150. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11822993).
28. Kroutil L.A., Van Brunt D.L., Herman-Stahl M.A., Heller D.C., Bray R.M., Penne M.A. Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence 2006, 84(2):135-143. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16480836).
29. Lane S.D., Cherek D.R., Tcheremissine O.V., Lieving L.M., Pietras C.J. Acute marijuana effects on human risk taking. Neuropsychopharmacology 2005, 30(4):800-809. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15775958).
30. Lee S.S., Humphreys K.L., Flory K., Liu R., Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clinical Psychology Review 2011, 31(3):328-341. 10.1016/j.cpr.2011.01.006.
31. Linssen A.M., Sambeth A., Vuurman E.F., Riedel W.J. Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. International Journal of Neuropsychopharmacology 2014, 1-17. 10.1017/S1461145713001594.
32. Low K.G., Gendaszek A.E. Illicit use of psychostimulants among college students: A preliminary study. Psychology, Health & Medicine 2002, 7(3):283-287.
33. Martin C.S., Clifford P.R., Clapper R.L. Patterns and predictors of simultaneous and concurrent use of alcohol, tobacco, marijuana, and hallucinogens in first-year college students. Journal of Substance Abuse 1992, 4(3):319-326. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1458048).
34. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics 1971, 12:245-258.
35. Massello W., Carpenter D.A. A fatality due to the intranasal abuse of methylphenidate (Ritalin). Journal of Forensic Sciences 1999, 44(1):220-221.
36. McCabe S.E., Boyd C.J., Young A. Medical and nonmedical use of prescription drugs among secondary school students. The Journal of Adolescent Health 2007, 40(1):76-83. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17185209).
37. McCabe S.E., Cranford J.A., Boyd C.J. The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample. Drug and Alcohol Dependence 2006, 84(3):281-288. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16621337).
38. McCabe S.E., Cranford J.A., Morales M., Young A. Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. Journal of Studies on Alcohol 2006, 67(4):529-537. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16736072).
39. McCabe S.E., Knight J.R., Teter C.J., Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005, 100(1):96-106. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15598197).
40. McCabe S.E., Teter C.J., Boyd C.J. The use, misuse and diversion of prescription stimulants among middle and high school students. Substance Use and Misuse 2004, 39(7):1095-1116. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15387205).
41. McCabe S.E., Teter C.J., Boyd C.J. Medical use, illicit use and diversion of prescription stimulant medication. Journal of Psychoactive Drugs 2006, 38(1):43-56. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16681175).
42. McCabe S.E., West B.T. Medical and nonmedical use of prescription stimulants: results from a national multicohort study. Journal of the American Academy of Child and Adolescent Psychiatry 2013, 52(12):1272-1280. 10.1016/j.jaac.2013.09.005.
43. McDonald J., Schleifer L., Richards J.B., de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 2003, 28(7):1356-1365. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12784123).
44. Mendrek A., Monterosso J., Simon S.L., Jarvik M., Brody A., Olmstead R., et al. Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Addictive Behaviors 2006, 31(5):833-844. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16009504).
45. Mittleman M.A., Lewis R.A., Maclure M., Sherwood J.B., Muller J.E. Triggering myocardial infarction by marijuana. Circulation 2001, 103(23):2805-2809. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11401936).
46. Molina B.S., Hinshaw S.P., Eugene Arnold L., Swanson J.M., Pelham W.E., Hechtman L., et al. Adolescent substance use in the multimodal treatment study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry 2013, 52(3):250-263. 10.1016/j.jaac.2012.12.014.
47. Nandam L.S., Hester R., Wagner J., Cummins T.D., Garner K., Dean A.J., et al. Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biological Psychiatry 2011, 69(9):902-904. 10.1016/j.biopsych.2010.11.014.
48. Nissen S.E. ADHD drugs and cardiovascular risk. The New England Journal of Medicine 2006, 354(14):1445-1448. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16549404).
49. Olfson M., Huang C., Gerhard T., Winterstein A.G., Crystal S., Allison P.D., et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2012, 51(2):147-156. 10.1016/j.jaac.2011.11.008.
50. Oliveto A.H., Bickel W.K., Hughes J.R., Shea P.J., Higgins S.T., Fenwick J.W. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. The Journal of Pharmacology and Experimental Therapeutics 1992, 261(3):885-894. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1602393).
51. Penetar D.M., Kouri E.M., Gross M.M., McCarthy E.M., Rhee C.K., Peters E.N., et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug and Alcohol Dependence 2005, 79(2):211-223. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16002030).
52. Pliszka S.R., Crismon M.L., Hughes C.W., Corners C.K., Emslie G.J., Jensen P.S., et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45(6):642-657. 10.1097/01.chi.0000215326.51175.eb.
53. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ: Canadian Medical Association Journal=Journal De l'Association Medicale Canadienne 2001, 165(8):1039-1044. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11699699).
54. Ramaekers J.G., Kauert G., van Ruitenbeek P., Theunissen E.L., Schneider E., Moeller M.R. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006, 31(10):2296-2303. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16572123).
55. Ranganathan M., D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006, 188(4):425-444. 10.1007/s00213-006-0508-y.
56. Robison L.M., Sclar D.A., Skaer T.L., Galin R.S. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clinical Pediatrics 1999, 38(4):209-217. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10326176).
57. Rush C.R., Essman W.D., Simpson C.A., Baker R.W. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. Journal of Clinical Psychopharmacology 2001, 21(3):273-286. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11386490).
58. Rush C.R., Kollins S.H., Pazzaglia P.J. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Experimental and Clinical Psychopharmacology 1998, 6(1):32-44. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9526144).
59. Safer D.J., Zito J.M., Fine E.M. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996, 98(6 Pt 1):1084-1088. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8951257).
60. Schensul J.J., Convey M., Burkholder G. Challenges in measuring concurrency, agency and intentionality in polydrug research. Addictive Behaviors 2005, 30(3):571-574. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15718073).
61. Sembower M.A., Ertischek M.D., Buchholtz C., Dasgupta N., Schnoll S.H. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. Journal of Addictive Diseases 2013, 32(1):26-38. 10.1080/10550887.2012.759880.
62. Sidney S. Cardiovascular consequences of marijuana use. Journal of Clinical Pharmacology 2002, 42(11 Suppl.):64S-70S. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12412838).
63. Stoops W.W., Glaser P.E., Fillmore M.T., Rush C.R. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. Journal of Psychopharmacology 2004, 18(4):534-543. 10.1177/0269881104047281.
64. Teter C.J., McCabe S.E., Cranford J.A., Boyd C.J., Guthrie S.K. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health 2005, 53(6):253-262. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15900989).
65. Toennes S.W., Ramaekers J.G., Theunissen E.L., Moeller M.R., Kauert G.F. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. Journal of Analytical Toxicology 2008, 32(7):470-477. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18713514).
66. Vadhan N.P., Hart C.L., van Gorp W.G., Gunderson E.W., Haney M., Foltin R.W. Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. Journal of Clinical and Experimental Neuropsychology 2007, 29(4):357-364. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17497559).
67. Visser S.N., Blumberg S.J., Danielson M.L., Bitsko R.H., Kogan M.D. State-based and demographic variation in parent-reported medication rates for attention-deficit/hyperactivity disorder, 2007-2008. Preventing Chronic Disease 2013, 10:E09. 10.5888/pcd9.120073.
68. Visser S.N., Danielson M.L., Bitsko R.H., Holbrook J.R., Kogan M.D., Ghandour R.M., et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. Journal of the American Academy of Child and Adolescent Psychiatry 2014, 53(1):34-46.e2. 10.1016/j.jaac.2013.09.001.
69. Wachtel S.R., ElSohly M.A., Ross S.A., Ambre J., de Wit H. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002, 161(4):331-339. 10.1007/s00213-002-1033-2.
70. Westover A.N., Halm E.A. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovascular Disorders 2012, 12:41. 10.1186/1471-2261-12-41.
71. Wilens T.E., Gignac M., Swezey A., Monuteaux M.C., Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45(4):408-414. (S0890-8567(09)62060-8 [pii]). 10.1097/01.chi.0000199027.68828.b3.
72. Williams R.J., Goodale L.A., Shay-Fiddler M.A., Gloster S.P., Chang S.Y. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. The American Journal on Addictions 2004, 13(4):381-389. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15370936).
73. Winterstein A.G., Gerhard T., Kubilis P., Saidi A., Linden S., Crystal S., et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012, 345:e4627. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22809800).
74. Winterstein A.G., Gerhard T., Shuster J., Johnson M., Zito J.M., Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007, 120(6):e1494-e1501. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18055666).
75. Zito J.M., Safer D.J., dosReis S., Gardner J.F., Boles M., Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000, 283(8):1025-1030. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10697062).
76. Zosel A., Bartelson B.B., Bailey E., Lowenstein S., Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS((R))) System. Journal of the American Academy of Child and Adolescent Psychiatry 2013, 52(2):196-204.e2. 10.1016/j.jaac.2012.11.014.